Welcome to our dedicated page for Stagezero Life news (Ticker: SZLSF), a resource for investors and traders seeking the latest updates and insights on Stagezero Life stock.
StageZero Life Sciences (SZLSF) is a healthcare company revolutionizing cancer detection with its proprietary liquid biopsy multi-cancer diagnostic test, Aristotle®. By screening for multiple cancers from a single blood sample, Aristotle® offers high sensitivity and specificity for each cancer type. The company also provides oncologist-led treatment protocols, such as the COC Protocol, to target metabolic cancer pathways for improved patient outcomes. With a focus on early detection and unique telehealth programs like AVRT, StageZero is dedicated to advancing cancer care. Through its clinical laboratory in Richmond, Virginia, StageZero continues to innovate in the fight against cancer.
StageZero Life Sciences (TSX:SZLS, OTCQB:SZLSF) reports Q2 2022 financial results with $2.3 million in revenue for H1, down from $2.9 million in H1 2021. The company saw a net loss of $1.9 million compared to $3.0 million last year. In Q2 alone, revenue grew to $1.0 million, up from $0.4 million in 2021, but was offset by a net loss of $1.3 million. Significant operational updates include raising CAD 1.87 million and expanding cancer testing offerings. The CEO emphasized a renewed focus on cancer testing and employer health initiatives as pandemic restrictions ease.
StageZero Life Sciences is set to release its second quarter operational and financial results on August 16, 2022, prior to market opening. The results will be discussed in a conference call at 8:30 a.m. EDT, hosted by Chairman and CEO James Howard-Tripp. The company specializes in early cancer detection through innovative diagnostics such as the mRNA multi-cancer panel Aristotle, validated in over 9,000 patients. Additionally, StageZero provides telehealth programs aimed at cancer management and prevention, underlined by its commitment to improving patient outcomes.
StageZero Life Sciences announced that shareholders approved all resolutions at the annual meeting held on June 28, 2022. Key results include:
- Election of directors: James Howard-Tripp (84%), Rory Riggs (89%), Harry Glorikian (89%), Garth MacRae (89%);
- Appointment of auditors: SRCO Professional Services LLP with 97% approval;
- Stock Option Plan renewal: 77% votes in favor.
CEO James Howard-Tripp emphasized the importance of 2021 and the potential for 2022 to generate significant revenue.
StageZero Life Sciences (TSX:SZLS) (OTCQB:SZLSF) announced the resignation of CFO and COO Matthew Pietras, effective immediately. Pietras will assist in transitioning to a new CFO. The company expressed gratitude for his contributions over the past 9 months during significant organizational changes, including the incorporation of Care Oncology. StageZero focuses on advanced diagnostics for early cancer detection and includes programs like the COC Protocol for cancer management and AVRT for chronic disease prevention.
StageZero Life Sciences has partnered with DiagnoseAtHome to broaden access to its multi-cancer blood test, Aristotle, in Canada and the USA. This test uses advanced mRNA gene expression technology to simultaneously screen for various cancers from a single blood sample, boasting high sensitivity and specificity. The collaboration aims to enhance early cancer screening accessibility for patients through at-home testing solutions, aligning with StageZero's growth strategy. The Aristotle test has been validated in over 9,000 patients and is recognized as a next-generation diagnostic tool.
StageZero Life Sciences (SZLSF) reported its Q1 2022 financial results, generating $1.3 million in revenue and a net loss of $0.6 million, significantly reduced from a $7.3 million loss in Q1 2021. Adjusted EBITDA for the quarter was $2.6 million. Key operational highlights include the successful integration of Care Oncology and the launch of the AVRT program in the US and UK. The company has shifted its focus back to cancer testing as COVID-19 testing revenue declines, which is expected.
StageZero Life Sciences has launched the COC Plus Program aimed at improving cancer treatment through nutrition and health interventions. This new program complements the existing COC Protocol and includes specialized blood tests, consultations with metabolic oncologists, and tailored health strategies. The initiative reflects the company's commitment to enhancing patient care globally. The growth strategy aligns with developing innovative solutions in cancer management, leveraging existing protocols established by the company's expert team.
StageZero Life Sciences (TSX:SZLS) will release its Q1 2022 financial results on May 17, 2022, before market opening. The company's Chairman and CEO, James Howard-Tripp, will lead a conference call at 8:30 a.m. EDT to discuss operational results and business developments. StageZero focuses on early cancer detection and management through innovative diagnostics and telehealth programs, including its proprietary mRNA multi-cancer panel, Aristotle®. The company highlights its commitment to improving patient outcomes through developed protocols and advanced testing capabilities.
StageZero Life Sciences has provided a corporate update amidst share price fluctuations, asserting no changes to their corporate strategy. Despite pricing pressures, the company reported $1.50 million in revenue for Q4 2021, and highlighted key milestones, including the integration of Care Oncology and the launch of the Aristotle test. Additionally, they closed private placements totaling CAD$6.07 million. Executives expressed confidence in their operational fundamentals and strategic vision, aiming to enhance early cancer detection and management through innovative diagnostics.
StageZero Life Sciences reported its financial results for Q4 2021, showing $5.1 million in revenue for the year, a 22% increase from 2020. Gross profit rose to $1.2 million, while net loss was $7.5 million, or $0.11 per share. During Q4, the company generated $1.5 million in revenue but faced a net loss of $2.3 million. Key operational milestones included integration of Care Oncology and the launch of the Aristotle test in the Greater Toronto Area. The company closed a CAD$4.2 million private placement.
FAQ
What is the current stock price of Stagezero Life (SZLSF)?
What is the market cap of Stagezero Life (SZLSF)?
What is Aristotle®?
What is the COC Protocol?
What is AVRT?
Where is StageZero's clinical laboratory located?
What sets StageZero apart in cancer care?
